Hypera S.A. HYPMY
Set alert
At close · Oct 30
- YTD
- -6.04%
- 1 year
- -15.43%
- Open
- 4.01
- Prev close
- 3.99
- Mkt cap
- 2.74B
- Vol
- 1.01K
- Avg vol
- 101.78K
- EPS
- 0.52
- P/E
- 7.48
More statistics
- Low
- 3.83
- High
- 4.01
- Earnings
- Nov 11, 2026
News
4 days ago seekingalpha.com
Hypera S.A. (HYPMY) Q3 2026 Earnings Call Transcript
Hypera S.A. (HYPMY) Q3 2026 Earnings Call Transcript
2 weeks ago defenseworld.net
Lyra Therapeutics (OTCMKTS:LYRA) versus Hypermarcas (OTCMKTS:HYPMY) Head-To-Head Analysis
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two…
3 weeks ago defenseworld.net
Hypermarcas (OTCMKTS:HYPMY) Reaches New 12-Month High – Should You Buy?
Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price reached a new 52-week high on Monday. The stock traded as high as $5.65 and last traded at $5.65, with a volume of 5784 shares trading…
4 weeks ago defenseworld.net
Hypermarcas (OTCMKTS:HYPMY) Stock Price Up 8% – Should You Buy?
Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s share price traded up 8% during trading on Thursday. The stock traded as high as $4.99 and last traded at $4.99. Approximately 1,842 shares changed…
1 month ago defenseworld.net
Contrasting Hypermarcas (OTCMKTS:HYPMY) and Ensysce Biosciences (NASDAQ:ENSC)
Ensysce Biosciences (NASDAQ: ENSC - Get Free Report) and Hypermarcas (OTCMKTS:HYPMY - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
2 months ago defenseworld.net
Hypermarcas (OTCMKTS:HYPMY) Shares Pass Below Two Hundred Day Moving Average – Here’s What Happened
Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $4.34 and traded as low as…
2 months ago seekingalpha.com
Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript
Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript
6 months ago defenseworld.net
Hypermarcas (OTCMKTS:HYPMY) Sees Large Increase in Short Interest
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw a large increase in short interest in March. As of March 31st, there was short interest totaling 3,024 shares, an increase of 18,800.0% from the…
8 months ago defenseworld.net
Hypermarcas (OTCMKTS:HYPMY) Short Interest Update
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 50,686 shares, a growth of…
-
8 months ago defenseworld.net
Hypermarcas (OTCMKTS:HYPMY) Short Interest Update
Hypermarcas (OTCMKTS:HYPMY - Get Free Report) saw a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 50,686 shares, a growth of…
10 months ago defenseworld.net
Hypermarcas (OTCMKTS:HYPMY) Shares Gap Up – Here’s What Happened
Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price gapped up before the market opened on Wednesday. The stock had previously closed at $4.00, but opened at $4.13. Hypermarcas shares last…
1 year ago seekingalpha.com
Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript
Hypera S.A. (OTCPK:HYPMY) Q3 2025 Earnings Call October 29, 2025 10:00 AM EDT Company Participants Breno Pires de Oliveira - Chief Executive Officer Ramon Frutuoso Silva - CFO & Investor Relation…
1 year ago reuters.com
Brazil's Hypera announces new majority stakeholder group
Brazilian drugmaker Hypera said on Monday that shareholders executed an agreement by which a new control group now holds 53% of share capital.
1 year ago seekingalpha.com
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
Hypera S.A. (OTCPK:HYPMY) Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Breno Toledo Pires de Oliveira - Chief Executive Officer Adalmario Ghovatto Satheler do…
1 year ago seekingalpha.com
Hypera: Short-Term Pain For Long-Term Gain
Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have…
6 years ago seekingalpha.com
Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio
In Reais, I believe there is a 30% upside on Hypera S.A. due to improving margins as the company increases its operation by acquiring other brands and internal development. 75% of the Sell-Side…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday